| 前收盘价格 | 0.740 |
| 收盘价格 | 0.740 |
| 成交量 | 1,528,382 |
| 平均成交量 (3个月) | 2,477,813 |
| 市值 | 978,716,608 |
| 预期市盈率 (P/E Forward) | 6.75 |
| 价格/销量 (P/S) | 2,554.14 |
| 股市价格/股市净资产 (P/B) | 4.21 |
| 52周波幅 | |
| 利润日期 | 26 Feb 2025 - 3 Mar 2025 |
| 营业利益率 (TTM) | -164,535.56% |
| 稀释每股收益 (EPS TTM) | -0.530 |
| 季度收入增长率 (YOY) | -68.30% |
| 流动比率 (MRQ) | 2.94 |
| 营业现金流 (OCF TTM) | -161.02 M |
| 杠杆自由现金流 (LFCF TTM) | -94.87 M |
| 资产报酬率 (ROA TTM) | -83.43% |
| 股东权益报酬率 (ROE TTM) | -3,383.08% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (AU) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | OPTHEA FPO [OPT] | - | - |
AIStockmoo 评分
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | -4.5 |
| 技术平均移动指标 | -1.0 |
| 技术振荡指标 | 4.0 |
| 平均 | -0.38 |
|
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 5.22% |
| 机构持股比例 | 41.82% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合